| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
-SEC Filing
JMP Securities analyst Jonathan Wolleben upgrades Spruce Biosciences (NASDAQ:SPRB) from Market Perform to Market Outperform ...
-SEC Filing
Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel ...